MAPT and Parkinson disease: A substantial part of traditional treatments for neurodegenerative diseases including AD, cerebral amyloid angiopathy, frontotemporal dementia, mild cognitive impairment, and PD are based on immunotherapy, most of them active and passive immunotherapy trials conducted based on amyloid, tau, and α-synuclein targeting (Alzforum.org; https://www.alzforum.org/therapeutics).